

**The Food and Drug Administration's (FDA's)  
2015 ORSI Science Symposium  
April 27, 2015  
SPEAKER ABSTRACTS AND BIOGRAPHIES**

**Session 4: Broad Agency Announcement (BAA) Research Contract Program Presentations – 1:45-3:00 PM**

Speaker name and title	<b>Joseph V. Pergolizzi Jr., MD Chief Operating Officer NEMA Research Inc.</b>
Contractor	<b>NEMA Research Inc.</b>
Biography	<p><b>Dr. Pergolizzi earned a BS in physical chemistry from St. John’s University and an MD with highest honors from Ross University School of Medicine. Dr. Pergolizzi completed his residency in anesthesia at Georgetown University School of Medicine and a clinical research fellowship in the Department of Medicine at Johns Hopkins University School of Medicine. He has served as Chief Operating Officer for NEMA Research Inc. since 1997 with global business corporate lead direct responsibilities for turn-key clinical trial management and implementation (Phase I-IV). Prior to joining NEMA, Dr. Pergolizzi was the Director of Business Development and Financial and Affairs for the Johns Hopkins University school of Medicine’s Clinical Trials Unit.</b></p> <p><b>Dr. Pergolizzi is an internationally recognized expert in health economics and outcomes research, pain medicine, anesthesia, internal medicine, clinical research, and drug discovery. He is the author of more than 100 peer reviewed articles, abstracts, platform presentations and book chapters. Dr. Pergolizzi serves as editor-in-chief of The Clinical Researcher, and is an editorial board member or reviewer for many scientific journals including JAMA, Pain Practice, Lancet, and The Scientific World Journal of Anesthesia. He is also an invited feature editor of Pain Medicine. Joseph V. Pergolizzi, Jr., MD, is an adjunct Assistant Professor in the Department of Medicine at Johns Hopkins University School of Medicine, an Adjunct Associate Professor in the Department of Pharmacology at Temple University School of Medicine in Philadelphia, PA, and a senior partner in the Naples Anesthesia and Pain Associates Group of Southwest Florida. Dr. Pergolizzi is the Co-Founder and Chairman of the Board for the Association of Chronic Pain Patients. He is a member of the board of directors and treasurer for the Coalition for Pain Education (COPE), co-founder and Director of Research at the International Pain Research and Treatment Foundation, and a member of the board of directors of the National Institute of Pain, and Always Healthcare. In addition, he serves as Chairman of the Scientific and Research Committee: Poster and Abstract Session for Pain Week, a multidisciplinary international medical conference sponsored by the American Society of Pain Educators, as well as serving as Facilitator and U.S. Board Member for the International Change Pain Initiative, a multidisciplinary Pan-European pain management educational medical consortium composed of globally recognized experts in pain medicine. He is also a committee member of the Food and Drug Administration’s Safe Use Initiative and has served on a number of NIH and VA grant review boards.</b></p>
Title of the project	<b>Nurse Pain Educator Pilot Program (NPE): A Method For Improving Communication About Pain Treatment</b>
Presentation Abstract	<b>Historically, chronic pain generally went undertreated for a variety of objective and subjective reasons, including: it is difficult to objectively diagnose, it is difficult to manage over a long periods of time, the commonly available medications have potential serious adverse effects, and there are patient-, healthcare-, and societal-concerns over opioid medications. More recently, in an effort to redress the under treatment of pain, the number of prescriptions of opioid analgesics has risen dramatically. However, paralleling the increased legitimate use has been a concomitant increase in opioid abuse, misuse, diversion and overdose related deaths. In an effort to address this problem, one approach has been to redesign opioid formulations and incorporate abuse-deterrent technologies. Though successful, this method has not been able to address the over prescription or over consumption problem with opioids, it has only begun to tackle the abuse and misuse issues. In the FDA Safe Use Initiative’s November 2009 report, the</b>

# The Food and Drug Administration's (FDA's)

## 2015 ORSI Science Symposium

April 27, 2015

### *SPEAKER ABSTRACTS AND BIOGRAPHIES*

FDA cited findings including the number of preventable adverse events due to medication errors, unintentional exposure, drug abuse, misuse, or self-harm may be addressed by educating patients, pharmacists, and clinicians. Keeping this though process in mind, the research goals of this project recognize that opioid abuse, misuse, and diversion may also be reduced through proper prescribing and physician/patient education. Communication between health care professionals (HCP) (including pharmacists) and patients can be greatly improved by: increasing the level of awareness of such things as potential drug-drug interactions; encouraging pharmacists to communicate to patients the importance of proper use and compliance; providing a resource of information to patients and their caregivers; and making available a resource that provides physicians with a comprehensive compilation of tools to aid responsible prescribing of pain medication. Education for all the stakeholders (clinicians, patients, caregivers, administrators, etc.) is the best first step to address the inadequacies that exist in the management of chronic pain today. To provide such education, this program looks to modify existing Nurse Educator models and by doing so will look to provide an opportunity to promote safe and appropriate management strategies. The program will examine the role and impact of a Nurse Pain Educator on the safe and appropriate use of opioid analgesics. More specifically, the program will look to increase the safe and appropriate use of opioid analgesics (e.g., reduced opioid consumption, reduced opioid prescribing) by establishing the Nurse Pain Educator (NPE) as essential figure in the education and management of chronic pain patients who are or will be prescribed opioids.